Scholar RockSRRK
SRRK
About: Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Employees: 196
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
548% more capital invested
Capital invested by funds: $696M [Q3] → $4.51B (+$3.81B) [Q4]
350% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 9 (+7) [Q4]
320% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 20
44% more call options, than puts
Call options by funds: $75.1M | Put options by funds: $52.2M
39% more funds holding
Funds holding: 160 [Q3] → 222 (+62) [Q4]
13% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 60
2.91% more ownership
Funds ownership: 108.55% [Q3] → 111.46% (+2.91%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for SRRK.
Financial journalist opinion
Based on 4 articles about SRRK published over the past 30 days
Negative
The Motley Fool
2 days ago
Why Scholar Rock Stock Took a Knock on Monday
Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes could reflect instability, indecision, or both in a company's decision-making.
Neutral
Business Wire
2 days ago
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion buildi.
Positive
The Motley Fool
1 week ago
Why Scholar Rock Holding Stock Topped the Market Today
Biotech stock Scholar Rock (SRRK 2.97%) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. This resulted in the stock bumping nearly 3% higher on the day.
Neutral
Business Wire
1 week ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards covering an aggregate of 156,650 shares of its common stock to 19 newly hired employees, consisting of inducement stock options to purchase an aggregate of 89,515 shares of common stock and.
Neutral
Business Wire
1 month ago
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for.
Positive
Benzinga
1 month ago
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment
Scholar Rock Holding Corp. SRRK said on Sunday the company will present new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
Neutral
Business Wire
1 month ago
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &a.
Neutral
Business Wire
1 month ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 113,800 shares of its common stock to seven newly hired employees, consisting of inducement stock options to p.
Neutral
Seeking Alpha
2 months ago
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript
Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial Officer Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan Gary Nachman - Raymond James Operator Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call.
Neutral
Business Wire
2 months ago
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2024. “Following positive topline results from the SAPPHIRE trial demonstrating apitegromab's potential to transform t.
Charts implemented using Lightweight Charts™